> For the complete documentation index, see [llms.txt](https://new-leaf-finance.gitbook.io/new-leaf-finance-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://new-leaf-finance.gitbook.io/new-leaf-finance-docs/cannabis-depin-and-development-hub.md).

# Cannabis DePIN & Development Hub

**PRODUCT DEVELOPMENT & MANUFACTURING (MEDICINAL)**

* R\&D Centre for medical, and pharmaceutical and nutraceutical development;
* Low-cost environment for conducting controlled trials and studies;
* Streamlined product development in an environment with high-potential interfacing of other natural medicines and compounds;
* Developing an EU-GMP licensed manufacturing facility for New Leaf and White-labeled product;
* International distribution to high-margin markets including Australia and Germany.

Colombia provides the ideal low cost/high quality production center for a bespoke New Leaf Cannabis ‘remedy’ development house.

Our GMP certified raw material and manufacturing facilities will offer a unique foundation for international distribution of affordable quality product lines.

<figure><img src="/files/AyEygSGs5Gfxa4jyibKB" alt=""><figcaption></figcaption></figure>

**INTERNATIONAL DEPIN PRODUCTION FACILITY (RECREATIONAL)**

* New Leaf controls a unique pre-roll production line technology;
* We propose a novel licensing, leasing and royalty arrangement to licensees;
* Licensees selected against a strategic market blueprint, developed by the Investment Committee;
* Major existing Producers with a strategic market position;
* Production lines funded and owned by the New Leaf Fund, in return for ongoing royalty payments;

New Leaf’s ambition is to establish the dominant DePIN pre-roll production ‘House’ of the international recreational markets, delegated to, and operated by, qualified existing Producers. This goal will also delegate product diversity to Licensee’s and individual market demand.